Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis
Open Access
- 13 November 2024
- journal article
- research article
- Published by Elsevier in Drug Resistance Updates
- Vol. 78, 101172
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysisThe Lancet Microbe, 2024
- First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trialThe Lancet Respiratory Medicine, 2024
- Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling studyBMJ Global Health, 2023
- The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and ChinaBMC Medicine, 2021
- Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccineNature Communications, 2021
- Understanding immunosenescence and its impact on vaccination of older adultsVaccine, 2020
- Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysisBMC Medicine, 2020
- Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling studyThe Lancet Global Health, 2019
- Long-term Persistence of Zoster Vaccine EfficacyClinical Infectious Diseases, 2014